Peak Bio, Inc. announced the appointment of one new independent board member, Michael Friedman, MBA as a Class III Director and as a member of the Company's Audit Committee and Compensation Committee. Mr. Friedman served as Senior Vice President at Ladenburg Thalmann & Co. Inc. Healthcare Investment Banking where he focused on M&A and capital markets from 2017 to 2023.

Mr. Friedman has worked with numerous biotech, pharmaceutical and healthcare services companies for over 15 years and has executed a significant number of M&A, IPO, leveraged finance, and equity follow-on transactions. Previously, Michael was an investment banker for Bank of America Merrill Lynch, Jefferies and Baird. He holds an MBA from the University of Chicago; Booth School of Business and he received his BBA from the University of Wisconsin.

The Company's Board of Directors believes Mr. Friedman's significant experience advising biopharmaceutical companies in M&A and finance qualifies him to serve on board of directors.